Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
Aurora Cannabis Reveals Latest Product Innovations: Ultra-High Potency Indicas And Strains For Veterans
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), announced on Tuesday developments in cannabis science from Aurora's research and genetics facility, Aurora Coast.
極光大麻股公司（納斯達克:ACB）（tsx:ACB）宣佈，週二在極光研究和遺傳科學設施Aurora Coast的大麻科學領域取得了進展。
The latest innovations from the Canadian medical cannabis giant include:
加拿大醫療大麻巨頭的最新創新包括：
- Aurora | CBD Varius (1g, 510 Cartridge);
- MedReleaf (Strains For Heroes) | Esprit De Corps (5g and 15g); a premium sativa (THC: 20-29%, CBD: 0-1%), developed under the Strains For Heroes initiative by Aurora with direct feedback from Veteran patients;
- MedReleaf | Sedamen (1g, 510 Cartridge) in a higher THC format;
- MedReleaf | Noculus (5g and 15g); an ultra-high potency indica, featuring THC levels between 25-31% and CBD content from 0-1%; and
- WMMC | Seasonal Stash – Frosted Alpine (10g); a limited-grown hybrid strain (THC: 24-30%; CBD: 0-1%).
- 極光 | CBD吸入器（1克，510毫米）；
- MedReleaf（英雄品種）| Esprit De Corps（5g和15g）；一種優質的薩提瓦（THC: 20-29%，CBD: 0-1%），由極光在英雄品種倡議下，與退伍軍人患者直接反饋合作開發；
- MedReleaf | Sedamen（1g，510毫米）以更高THC格式提供；
- MedReleaf | Noculus（5g和15g）；一種超高效力的靛青品種，THC含量介於25-31%，CBD含量在0-1%之間；和
- WMMC | 季節性儲藏品 – 霜凍高山（10g）；一種限量生產的雜交品種（THC: 24-30%，CBD: 0-1%）。
Read Also: Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs
閱讀更多：極光大麻在澳洲推出創新THC油產品，以滿足不同患者需求
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
"As a company committed to leading the way in terms of cannabis innovation, we are dedicated to putting patients first by harnessing the innovative solutions developed by our top researchers at Aurora Coast, our unique global research facility," Lana Culley, vice president of science and innovation at Aurora. "We strive to continuously raise the bar on product superiority and overall user experience so that we can deliver on our mission of providing patients with access to the very best medical cannabis."
作爲一家致力於在大麻股創新領域處於領先地位的公司，我們致力於通過利用極光海岸頂尖研究人員在全球獨特研究設施開發的創新解決方案，將患者放在首位，"極光科學和創新副總裁拉娜·卡利說。"我們努力不懈地提升產品優勢和用戶體驗，以便實現我們的使命，爲患者提供最優質的醫用大麻。"
The latest update from Aurora comes on the heels of its recently revealed lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands for Canadian consumers.
極光最新的消息發佈是在其最近公佈的創新產品系列（來自Greybeard，San Rafael '71和Tasty's品牌）之後，面向加拿大消費者。
Aurora reported its second quarter financial results, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.
極光報告了其第二季度財務業績，顯示營業收入爲CA$8110萬（$5830萬），較去年同期的CA$6310萬有所增長。
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
公司表示，與前一時期相比增長29%，其中全球醫療大麻業務增長41%，植物繁殖業務增長21%，略有偏低的消費大麻業務季度收入。
- UK Medical Cannabis Market Gets Boost With Aurora And Script Assist Collaboration
- 極光與Script Assist合作，爲英國醫療大麻市場注入活力。
ACB Price Action
ACB的價格行情
Aurora's shares traded 3.28% lower at $4.42 per share at the time of writing on Tuesday morning.
在週二早上寫作時，極光股價爲每股4.42美元，下跌了3.28%。
譯文內容由第三人軟體翻譯。
